Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Simvastatin on Uterine Leiomyoma Size

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03400826
Recruitment Status : Recruiting
First Posted : January 17, 2018
Last Update Posted : August 21, 2018
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
Johns Hopkins University

Tracking Information
First Submitted Date  ICMJE January 9, 2018
First Posted Date  ICMJE January 17, 2018
Last Update Posted Date August 21, 2018
Actual Study Start Date  ICMJE August 20, 2018
Estimated Primary Completion Date January 1, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 9, 2018)
Change in Tumor size volume pre and post study intervention [ Time Frame: Change from baseline to 12 weeks post intervention ]
Tumor size measured by ultrasound imaging comparing tumor volume using ultrasound imaging. The volume will be reported in Centimeter cubes. The largest radius of the tumor will be used to calculate the volume, this will be measured in centimeters.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03400826 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 8, 2018)
  • Clinical symptom improvement as determined by the Uterine Fibroid Symptom and Health Related Quality of Life Questionnaire. [ Time Frame: At visit 1 (Screening), At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4( 12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy ]
    The questionnaire used is the Uterine Fibroid Symptom and Health Related Quality of Life Questionnaire. This questionnaire is an effective and validated tool for detecting differences in symptom severity and health-related quality of life among patients with uterine fibroids. The scale for this questionnaire denotes symptom severity with lowest and highest possible scores of 8 and 40 respectively. Higher scores indicate greater severity of symptoms.
  • Adherence to the recommended treatment dosing [ Time Frame: At Visit 3 (6 weeks after start of study drug), and Visit 4 (12 weeks after start of the study drug) ]
    Based on review of patient diaries and counting of left over medications bought back by the subject. This will be reported as an overall percentage.
  • Subject retention [ Time Frame: At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4 (12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy. ]
    Based on presence at follow up visits to the study site. This will be determined as a simple percentage of subjects that stay in the study until the last visit.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 9, 2018)
  • Clinical symptom improvement as determined by the Uterine Fibroid Symptom and Health Related Quality of Life Questionnaire. [ Time Frame: At visit 1 (Screening), At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4( 12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy ]
    The questionnaire used is the Uterine Fibroid Symptom and Health Related Quality of Life Questionnaire. This questionnaire is an effective and validated tool for detecting differences in symptom severity and health-related quality of life among patients with uterine fibroids. The scale for this questionnaire denotes symptom severity with lowest and highest possible scores of 8 and 40 respectively. The scores will be used as a quantitative measure for symptom improvement.
  • Adherence to the recommended treatment dosing [ Time Frame: At Visit 3 (6 weeks after start of study drug), and Visit 4 (12 weeks after start of the study drug) ]
    Based on review of patient diaries and counting of left over medications bought back by the subject. This will be reported as an overall percentage.
  • Subject retention [ Time Frame: At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4 (12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy. ]
    Based on presence at follow up visits to the study site. This will be determined as a simple percentage of subjects that stay in the study until the last visit.
Current Other Pre-specified Outcome Measures
 (submitted: January 9, 2018)
Adverse events reporting by organ systems [ Time Frame: At visit 2 (start of the study drug intake), visit 3 (6 weeks after start of the study drug), visit 4 (12 weeks after start of the study drug), and follow up visit at 2 and 6 weeks post hysterectomy. ]
Based on patient reporting and study team evaluation utilizing CTCAE v.4
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Effects of Simvastatin on Uterine Leiomyoma Size
Official Title  ICMJE A Double-blinded, Phase II, Randomized Control Trial to Study the Effects of Simvastatin in Patients With Uterine Leiomyoma
Brief Summary The study aims to study the effect of simvastatin on the size of uterine fibroids.
Detailed Description The study is a phase II double blinded clinical trial to determine feasibility, safety and preliminary clinical efficacy of simvastatin to reduce leiomyoma size. Women with symptomatic fibroids planned to undergo surgical management for fibroids such as hysterectomy or myomectomy will be screened for participation. The eligible women will undergo pre-study evaluation to ascertain study eligibility.The study will enroll 60 participants in total, half will receive simvastatin and the other half will receive a placebo. The study drug and placebo will be an add on to the participants ongoing medical management of fibroids until surgery. The participants will be monitored at intervals for the effect of the drug on fibroid size and symptoms using ultrasound and quality of life questionnaires.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE
  • Fibroid Uterus
  • Fibroid Tumor
  • Leiomyoma
  • Fibromyoma
  • Leiomyoma, Uterine
Intervention  ICMJE
  • Drug: Simvastatin 40mg
    The Treatment Group subjects will orally intake encapsulated Simvastatin 40 mg tablets daily for the 12 weeks duration with water in the evening.
    Other Name: Simvastatin
  • Drug: Placebo 40 mg
    The Placebo group will orally intake encapsulated Starch 1500, 40 mg Placebo for 12 weeks duration with water in the evening.
    Other Name: Starch 1500 encapsulated
Study Arms  ICMJE
  • Experimental: Treatment Group
    The 30 participants randomized in this group will intake Simvastatin 40mg / day of orally at the same time in the evening, every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
    Intervention: Drug: Simvastatin 40mg
  • Placebo Comparator: Placebo Group
    The 30 participants randomized in this group will intake Placebo 40mg / day orally at the same time in the evening every day for the study duration of 12 weeks prior to undergoing hysterectomy/ myomectomy. The fibroid samples will be collected after the surgery to evaluate the effects of the study medication on the fibroid tissue.
    Intervention: Drug: Placebo 40 mg
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: January 9, 2018)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 1, 2024
Estimated Primary Completion Date January 1, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Signed informed written consent.
  • Gender: female.
  • Age: 18-55 years at time of signing consent.
  • BMI of subjects: < 45 kg/m2.
  • Uterine fibroids:
  • Diagnosed by ultrasound (MRI will be used only if ultrasound is inconclusive).
  • Number: any number of fibroids.
  • Location: submucosal or intramural.
  • At least one fibroid of diameter > 3cm.
  • Symptoms: one or more of the following symptoms of heavy menstrual bleeding (HMB), defined as: Experienced cyclic (22 to 35 days) abnormal uterine bleeding (heavy or prolonged) in at least 3 of the last 6 menstrual periods, including menstrual bleeding lasting 5 or more days or heavy bleeding per participant recall. Examples of heavy bleeding may include, but are not limited to the following:
  • Requires the use of double protection to manage menstrual bleeding.
  • Menstrual bleeding accompanied by the sensation of "gushing" or "flooding".
  • Saturates more than 1 tampon or sanitary pad per hour for 3 or more consecutive hours.
  • Regularly needs to change the tampon or sanitary pad at night or regularly soils bedclothes.
  • Heavy bleeding that affects work, school, or social activities.
  • Pelvic pain/ pressure likely caused by fibroids.
  • Plan for surgery (hysterectomy or myomectomy).
  • Normal Pap smear within the last year.
  • Use of contraception during study such as non-hormonal oral contraceptives, intrauterine devices (IUD)/ intrauterine systems (IUS), barrier contraceptives, abstinence or sterilization.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Previous or current uterine, cervical or ovarian cancer.
  • Current endometrial hyperplasia or history of atypical endometrial hyperplasia. Endometrial biopsy will be done during screening (if not done within last 12 months).
  • Suspicion of leiomyosarcoma.
  • Recent rapid growth of fibroids (i.e. doubling in size within 1-6 months period).
  • Unevaluated gynecologic abnormalities (unexplained vaginal bleeding, cervical dysplasia, or abnormal adnexal/ovarian mass).
  • Menopausal status.
  • Surgery is urgently indicated (< 3 months) for medical or social reasons.
  • Hemoglobin ≤ 6 g/dL.
  • Currently enrolled in another investigational study.
  • Mental condition or other barrier preventing informed written consent.
  • Allergy or hypersensitivity to simvastatin.
  • Current use of simvastatin or other drugs of the same class.
  • Concomitant administration of strong CYP3A4 inhibitors including itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, and cobicistat-containing products.
  • Concomitant administration of gemfibrozil, cyclosporine, or danazol, verapamil, diltiazem, amiodarone, diltiazem, dronedarone, amlodipine, ranolazine, lomitapide, and grapefruit juice.
  • Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels.( elevation of aspartate transaminase and/or alanine transaminase > 2 s.d. above the normal range at screening visit)
  • Known increased risk or diagnosis of a myopathy.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Mostafa Borahay, MD, PhD (410) 550-0337 mboraha1@jhmi.edu
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03400826
Other Study ID Numbers  ICMJE IRB00149869
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Johns Hopkins University
Study Sponsor  ICMJE Johns Hopkins University
Collaborators  ICMJE National Institutes of Health (NIH)
Investigators  ICMJE
Principal Investigator: Mostafa Borahay, MD, PhD Johsn Hopkins School Of Medicine
PRS Account Johns Hopkins University
Verification Date August 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP